A revolutionary technology is being evaluated in the ADOPT study to improve CAD diagnostic precision.

Each year, thousands of patients in the Netherlands undergo testing for chest pain to rule out or confirm CAD. While CCTA is a widely recommended first-line diagnostic tool due to its high sensitivity, it has limitations in specificity, often overestimating the severity of coronary artery stenosis. This can lead to unnecessary invasive procedures, increasing patient burden and healthcare costs.

A groundbreaking new study, the ADOPT study (Added value in diagnostic accuracy of CCTA with Cardiolens FFR-CT Pro® versus CCTA only using ICA and iFFR as standard of reference), is set to evaluate the added value of an advanced imaging technology, Cardiolens FFR-CT Pro®, in diagnosing coronary artery disease (CAD) more accurately. The study, conducted across multiple centers in the Netherlands with the organizing center being the Amsterdam University Medical Center (Amsterdam UMC), seeks to enhance the precision of computed tomography coronary angiography (CCTA) by incorporating functional flow reserve analysis using the innovative Cardiolens FFR-CT Pro® technology.

As one of the leading academic medical centers in Europe, Amsterdam UMC is recognized for its cutting-edge research and clinical excellence. It was formed through the merger of the two largest university hospitals in Amsterdam: the Academic Medical Center (AMC) and the VU University Medical Center (VUmc). Amsterdam UMC is committed to advancing cardiovascular research, focusing on the development of non-invasive diagnostic solutions that improve patient outcomes and reduce the need for unnecessary invasive procedures.

CCTA-derived fractional flow reserve (FFR-CT), a technique that extracts hemodynamic information from routine CCTA images, has shown promising results in improving diagnostic accuracy. The ADOPT study will assess whether Cardiolens FFR-CT Pro® provides superior accuracy in detecting functionally significant coronary artery stenosis when compared to CCTA alone, using invasive coronary angiography (ICA) and invasive fractional flow reserve (iFFR) as the gold standard.

By reducing unnecessary invasive diagnostic procedures, the study aims to enhance patient care, minimize complications, and optimize healthcare resource utilization. The results of the ADOPT study could pave the way for a new standard in CAD diagnostics, ensuring more precise and cost-effective care. With its extensive expertise and state-of-the-art facilities, Amsterdam UMC plays a crucial role in driving innovation in cardiovascular imaging, further solidifying its position as a global leader in medical research and patient care.